Ari Rosenberg

University of Chicago Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (4)

James Dolezal

Assistant Professor

Geisinger Medical Center

UNITED STATES

View details

Naomi Kiyota

Associate Professor

Kobe University Hospital

JAPAN

View details

John Cursio

Research Assistant Professor

University of Chicago

UNITED STATES

View details

Sue S. Yom

University of California, San Francisco

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ari Rosenberg

Research Interests

Explore related searches

Contact this professor

Articles (10)

Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review

Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer

Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma

Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer

Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience

Optimizing Treatment De‐Escalation in Head and Neck Cancer: Current and Future Perspectives

Collaborators (4)

James Dolezal

Naomi Kiyota

John Cursio

Sue S. Yom

Make your next move.